Literature DB >> 21736933

Integrative transcriptional analysis between human and mouse cancer cells provides a common set of transformation associated genes.

C Balestrieri1, M Vanoni, S Hautaniemi, L Alberghina, F Chiaradonna.   

Abstract

Mouse functional genomics is largely used to investigate relevant aspects of mammalian physiology and pathology. To which degree mouse models may offer accurate representations of molecular events underlining human diseases such as cancer is not yet fully established. Herein we compare gene expression signatures between a set of human cancer cell lines (NCI-60 cell collection) and a mouse cellular model of oncogenic K-ras dependent transformation in order to identify their closeness at the transcriptional level. The results of our integrative and comparative analysis show that in both species as compared to normal cells or tissues the transformation process involves the activation of a transcriptional response. Furthermore, the cellular mouse model of K-ras dependent transformation has a good degree of similarity with several human cancer cell lines and in particular with cell lines containing oncogenic Ras mutations. Moreover both species have similar genetic signatures that are associated to the same altered cellular pathways (e.g. Spliceosome and Proteasome) or to deregulation of the same genes (e.g. cyclin D1, AHSA1 and HNRNPD) detected in the comparison between cancer cells versus normal cells or tissues. In summary, we report one of the first in-depth analysis of global gene expression profiles of a K-ras dependent mouse cell model of transformation and a large collection of human cancer cells as compared to their normal counterparts. Taken together our findings show a strong correlation in the transcriptional and pathway alteration responses between the two species, therefore validating the use of the mouse model as an appropriate tool to investigate human cancer, and indicating that the comparative analysis, as described here, offers a useful approach to identify cancer-specific gene signatures.
Copyright © 2011 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2011        PMID: 21736933     DOI: 10.1016/j.biotechadv.2011.06.013

Source DB:  PubMed          Journal:  Biotechnol Adv        ISSN: 0734-9750            Impact factor:   14.227


  6 in total

Review 1.  Rationale and Methodology of Reprogramming for Generation of Induced Pluripotent Stem Cells and Induced Neural Progenitor Cells.

Authors:  Zuojun Tian; Fuzheng Guo; Sangita Biswas; Wenbin Deng
Journal:  Int J Mol Sci       Date:  2016-04-20       Impact factor: 5.923

Review 2.  Subcellular Performance of Nanoparticles in Cancer Therapy.

Authors:  Chen-Guang Liu; Ya-Hui Han; Ranjith Kumar Kankala; Shi-Bin Wang; Ai-Zheng Chen
Journal:  Int J Nanomedicine       Date:  2020-02-05

3.  Mitochondrial complex I inhibitors and forced oxidative phosphorylation synergize in inducing cancer cell death.

Authors:  Roberta Palorini; Tiziana Simonetto; Claudia Cirulli; Ferdinando Chiaradonna
Journal:  Int J Cell Biol       Date:  2013-04-09

4.  Cancer cell growth and survival as a system-level property sustained by enhanced glycolysis and mitochondrial metabolic remodeling.

Authors:  Lilia Alberghina; Daniela Gaglio; Cecilia Gelfi; Rosa M Moresco; Giancarlo Mauri; Paola Bertolazzi; Cristina Messa; Maria C Gilardi; Ferdinando Chiaradonna; Marco Vanoni
Journal:  Front Physiol       Date:  2012-09-12       Impact factor: 4.566

5.  Comparing Alzheimer's and Parkinson's diseases networks using graph communities structure.

Authors:  Alberto Calderone; Matteo Formenti; Federica Aprea; Michele Papa; Lilia Alberghina; Anna Maria Colangelo; Paola Bertolazzi
Journal:  BMC Syst Biol       Date:  2016-03-02

6.  K-Ras Activation Induces Differential Sensitivity to Sulfur Amino Acid Limitation and Deprivation and to Oxidative and Anti-Oxidative Stress in Mouse Fibroblasts.

Authors:  Gaia De Sanctis; Michela Spinelli; Marco Vanoni; Elena Sacco
Journal:  PLoS One       Date:  2016-09-29       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.